Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2015-01-13 |
Inflectis Bioscience (France) |
€1.75 million |
financing round |
Bpifrance (France) investor Participations Besançon (France) GO Capital (France) |
Rare diseases - Genetic diseases - Neurodegenerative diseases |
Financing round |
2015-01-12 |
Capricor Therapeutics (USA - CA) |
$1 million |
private placement |
CureDuchenne Ventures (USA - CA) |
Rare diseases - Neuromuscular diseases |
Private placement |
2015-01-12 |
UroSens (UK) |
£2 million |
financing round |
Longwall Venture Partners (UK) Northstar Ventures (UK) Esperante BV (The Netherlands) Cambridge Capital Group (UK) and other existing shareholders. |
Cancer - Oncology - Diagnostic |
Financing round |
2015-01-12 |
RedXPharma (UK) |
£15 million |
IPO |
|
Cancer - Oncology - Infectious diseases |
IPO |
2015-01-09 |
MaaT Pharma (France) |
€ 1 million |
financing round |
Seventure Partners (France) |
Gastrointestinal diseases - Infectious diseases |
Financing round |
2015-01-07 |
GenSight Biologics (France) Pixium Vision (France) Fondation Voir et Entendre (France) |
€ 18.5 million |
grant |
BpiFrance (France) |
Ophtalmological diseases |
Grant |
2015-01-07 |
Affimed (Germany) |
€ 2.4 million ($3 million) |
grant |
German Federal Ministry of Education and Research (BMBF) (Germany) |
Cancer - Oncology |
Grant |
2015-01-06 |
AveXis (USA - CA) |
$10 million |
series C financing round |
Deerfield Management (USA) Roche Venture Fund (Switzerland) |
Rare diseases - Neuromuscular diseases - Neurodegenerative diseases |
Series C financing round |
2015-01-06 |
Seres Health (USA - MA) |
$ 65 million |
series D financing round |
Nestlé Health Science (Switzerland) |
Infectious diseases - Inflammatory diseases - Metabolic diseases |
Series D financing round |
2015-01-05 |
Moderna Therapeutics (USA - MA) |
$450 Million |
|
Viking Global Investors LP (UK-USA), Invus (USA - MA), RA Capital Management (USA - MA), Wellington Management Company (USA - MA), AstraZeneca (UK), Alexion Pharmaceuticals (USA - CT), additional undisclosed existing investors |
Cancer - Oncology - Rare diseases - Cardiovascular diseases - Infectious diseases |
Fundraising |
2015-01-02 |
Apeptico (Austria) |
|
grant |
The Wellcome Trust (UK) |
Rare diseases |
Grant |
2015-01-01 |
Orphazyme (Denmark) |
€ 20 million |
series B financing round |
Kurma Partners (France) Idinvest Partners (France) Novo A/S (Denmark) Sunstone Capital (Denmark) Aescap Venture (The Netherlands) |
Genetic diseases - Rare diseases |
Series B financing round |
2014-12-23 |
Pieris (Germany) |
$13.56 million |
private placement |
|
|
Private placement |
2014-12-22 |
NewLink Genetics (USA - IO) Merck&Co (USA - NJ) |
$30 million |
grant |
Biomedical Advanced Research and Development Authority (USA) |
Infectious diseases |
Grant |
2014-12-18 |
Nutrinia (Israel) |
$12 million |
series C financing round |
OrbiMed (USA - NY) Jacobs Investment Company (USA - FL) Pontifax (Israel) |
Rare diseases - Gastrointestinal diseases - Digestive diseases |
Series C financing round |
2014-12-18 |
Ecrins Therapeutics (France) |
|
fundraising |
WiSEED (France) |
Cancer - Oncology |
Fundraising |
2014-12-17 |
IMMUNOSHAPE consortium (Midatech Pharma (UK) |
€3.8 million |
grant |
|
Allergic diseases - Autoimmune diseases - Cancer - Oncology |
Grant |
2014-12-16 |
GSK (UK) University of Oxford (UK) Centre Hospitalier Universitaire Vaudois (Switzerland) Bernhard-Nocht Institute (Germany) |
€15.1 million |
grant |
European Commission’s Horizon 2020 programme |
Infectious diseases |
Establishment of a new subsidiary in the EU |
2014-12-16 |
Kymab (UK) |
|
grant |
The Wellcome Trust (UK) |
Infectious diseases |
Grant |
2014-12-15 |
BerGenBio (Norway) |
NOK90 million ($15 million - €9.8 million) |
private placement |
|
Cancer - Oncology - Rare diseases |
Private placement |